Dimerix (ASX:DXB) has provided an update on its ACTION3 Phase 3 clinical trial of DMX-200 in a rare kidney disease, Focal Segmental Glomerular Sclerosis …
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 28, 2025 Australian Biotech
Latest Video
New Stories
-
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - -
Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis
April 28, 2025 - - Australian Biotech -
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 28, 2025 - - Australian Biotech -
Government funding for new nasal spray ends three-decade drought
April 27, 2025 - - Latest News -
Repurposed diabetes drug could deliver gains for people living with major joint pain
April 27, 2025 - - Latest News -
March PBAC delivers outcome for high profile pre-funded cancer therapy
April 27, 2025 - - Latest News -
TGA approves new indication for GSK's RSV vaccine
April 24, 2025 - - Latest News